九年前，莉萨·海恩斯（Lisa Haines）悲观地得知，她之前通过化疗抑制的肺癌又复发了。正当这名患者准备接受现实，主治医生推荐了一种免疫疗法，Opdivo。

Following its initial approval at 150 mg, trastuzumab-strf has also been approved at 420 mg for the treatment of several HER2 ...

当乳腺癌扩散到大脑时，会导致严峻的后果，患者通常只有六个月的生命。临床统计表明，HER2阳性乳腺癌女性在多达55％的病例中倾向于发生脑转移。针对脑转移的乳腺癌细胞，目前化学疗法药物通常无效，因为它们无法穿越血脑屏障。

Adjuvant trastuzumab reveals associations with improved disease-free survival in 1-year vs 9-week administration of the drug ...

A 22-year-old LASU student is urgently seeking N15 million financial assistance as she battles an aggressive form of breast ...

Accord BioPharma received FDA approval for 420mg HERCESSI, a biosimilar to Herceptin to treat various kinds of ...

"Neoadjuvant therapy” refers to supplemental cancer treatment you receive before your primary treatment. Adjuvant therapies, ...

High TILs may predict which patients with early HER2-positive breast cancer may have a reduced risk for disease relapse or ...

In a 10-year analysis of the ShortHER trial, high tumor-infiltrating lymphocytes were associated with improved survival in ...

Jazz Pharmaceuticals has posted fresh phase 2 data on zanidatamab that show the HER2-targeted bispecific antibody kept 59% of ...

The US Food and Drug Administration (FDA) has approved a 420 mg dosage strength of Hercessi (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab). Hercessi, a HER2/neu receptor antagonist, is ...

Live-cell microscopy routinely provides massive amount of time-lapse images of complex cellular systems under various physiological or therapeutic conditions. However, this wealth of data remains ...